Blurbs

Analysts Offer Insights on Healthcare Companies: Microbot Medical (MBOT) and BioNTech SE (BNTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Microbot Medical (MBOTResearch Report) and BioNTech SE (BNTXResearch Report).

Microbot Medical (MBOT)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Microbot Medical today and set a price target of $20.00. The company’s shares closed last Thursday at $6.27.

According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -28.6% and a 23.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Oncternal Therapeutics, and Oramed Pharmaceuticals.

Currently, the analyst consensus on Microbot Medical is a Moderate Buy with an average price target of $20.00.

See today’s best-performing stocks on TipRanks >>

BioNTech SE (BNTX)

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on BioNTech SE today and set a price target of $200.00. The company’s shares closed last Thursday at $170.56.

According to TipRanks.com, Papadakis is a 3-star analyst with an average return of 3.6% and a 56.4% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Novo Nordisk, and Moderna.

BioNTech SE has an analyst consensus of Hold, with a price target consensus of $249.89, a 44.4% upside from current levels. In a report issued on March 30, J.P. Morgan also maintained a Hold rating on the stock with a $183.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MBOT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos